Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7983003 | 0.85 | KDM4E (0.67) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL8350565 | 0.80 | KDM4E (0.71) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL14759162 | 0.80 | KDM4E (0.71) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL5359262 | 0.80 | KDM4E (0.71) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| Hydrochloric Acid SCHEMBL14759243 | 0.78 | KDM4E (0.69) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL7980785 | 0.78 | KDM4E (0.62) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL24273206 | 0.77 | KDM4E (0.67) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL24862850 | 0.77 | KDM4E (0.67) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL21577705 | 0.77 | KDM4E (0.61) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL7986855 | 0.77 | KDM4E (0.56) | KDM4EALDH1A1RAB9ANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530224-A | Pyrimidinone compound and application thereof | 深圳安泰维生物医药有限公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-2994467-A1 | ARYLQUINAZOLINES | Merck Patent GmbH (DE) | 2016-03-16 | — | — | EP | disclosed |
| WO-2014183850-A1 | ARYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | WO | disclosed |
| US-7217711-B2 | Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-15 | — | — | US | disclosed |
| US-20050171093-A1 | New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171093-A1 | New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions | DPP4, DPP3, DPP7 | KDM4E 844/4885ALDH1A1 285/4885RAB9A 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.